- Home
- RBOT vs LPTX Comparison
RBOT vs LPTX Comparison
Compare RBOT & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RBOT
- LPTX
- Stock Information
- Founded
- RBOT 2014
- LPTX 2011
- Country
- RBOT United States
- LPTX United States
- Employees
- RBOT N/A
- LPTX N/A
- Industry
- RBOT Medical Specialities
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RBOT Health Care
- LPTX Health Care
- Exchange
- RBOT Nasdaq
- LPTX Nasdaq
- Market Cap
- RBOT 34.9M
- LPTX 35.4M
- IPO Year
- RBOT N/A
- LPTX N/A
- Fundamental
- Price
- RBOT $4.58
- LPTX $0.41
- Analyst Decision
- RBOT Hold
- LPTX Hold
- Analyst Count
- RBOT 1
- LPTX 1
- Target Price
- RBOT $7.00
- LPTX N/A
- AVG Volume (30 Days)
- RBOT 86.6K
- LPTX 1.5M
- Earning Date
- RBOT 11-13-2025
- LPTX 11-13-2025
- Dividend Yield
- RBOT N/A
- LPTX N/A
- EPS Growth
- RBOT N/A
- LPTX N/A
- EPS
- RBOT N/A
- LPTX N/A
- Revenue
- RBOT N/A
- LPTX N/A
- Revenue This Year
- RBOT N/A
- LPTX N/A
- Revenue Next Year
- RBOT N/A
- LPTX N/A
- P/E Ratio
- RBOT N/A
- LPTX N/A
- Revenue Growth
- RBOT N/A
- LPTX N/A
- 52 Week Low
- RBOT $4.50
- LPTX $0.22
- 52 Week High
- RBOT $19.00
- LPTX $3.92
- Technical
- Relative Strength Index (RSI)
- RBOT 33.93
- LPTX 41.91
- Support Level
- RBOT $5.14
- LPTX $0.40
- Resistance Level
- RBOT $5.50
- LPTX $0.56
- Average True Range (ATR)
- RBOT 0.40
- LPTX 0.05
- MACD
- RBOT -0.12
- LPTX -0.02
- Stochastic Oscillator
- RBOT 4.43
- LPTX 4.68
About RBOT Vicarious Surgical Inc.
Vicarious Surgical Inc designs a surgical robot that enables surgeons to perform minimally invasive surgery with 3D visualization and accurate control. Its Vicarious Surgical Robotic System is designed with a focus on abdominal access and visualization through a single port.
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.